Brief: Halozyme Announces Global Collaboration And License Agreement With Gsk To Develop Subcutaneous Formulations Of Multiple Promising Oncology Targets

Halozyme Therapeutics

07/05/2026 14:10

May 7 (Reuters) - Halozyme Therapeutics Inc HALO.O:

HALOZYME ANNOUNCES GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH GSK TO DEVELOP SUBCUTANEOUS FORMULATIONS OF MULTIPLE PROMISING ONCOLOGY TARGETS

HALOZYME THERAPEUTICS INC - ANNOUNCES GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH GSK

HALOZYME THERAPEUTICS INC - FIRST CLINICAL TRIAL PROJECTED TO INITIATE IN 2026

HALOZYME THERAPEUTICS INC - GSK TO MAKE UPFRONT AND MILESTONE PAYMENTS; HALOZYME ENTITLED TO ROYALTIES

HALOZYME THERAPEUTICS INC - COLLABORATION INCLUDES OPTION FOR ADDITIONAL FUTURE TARGETS

Source text: ID:nPn7RDj4ra

Further company coverage: HALO.O

 ((Reuters.Briefs@thomsonreuters.com;))